Antibody drop in newborns congenitally infected by<i>Trypanosoma cruzi</i>treated with benznidazole

Simple item page
dc.contributor.authorJean‐Philippe Chippaux
dc.contributor.authorAlejandra N. Salas Clavijo
dc.contributor.authorJosé Santalla
dc.contributor.authorJorge R. Postigo
dc.contributor.authorDominik T. Schneider
dc.contributor.authorLaurent Brutus
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:08:55Z
dc.date.available2026-03-22T14:08:55Z
dc.date.issued2009
dc.descriptionCitaciones: 42
dc.description.abstractRecovery may be confirmed in most cases at 10 months. The CSP test was compared to Chagatest v3.0 ELISA and appeared to give a reliable response. The decrease rate of antibodies does not depend on treatment modes.
dc.identifier.doi10.1111/j.1365-3156.2009.02431.x
dc.identifier.urihttps://doi.org/10.1111/j.1365-3156.2009.02431.x
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/44822
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofTropical Medicine & International Health
dc.sourceInstitut de Recherche pour le Développement
dc.subjectBenznidazole
dc.subjectTrypanosoma cruzi
dc.subjectSerology
dc.subjectChagas disease
dc.subjectAntibody
dc.subjectMedicine
dc.subjectParasitemia
dc.subjectVirology
dc.subjectImmunology
dc.titleAntibody drop in newborns congenitally infected by<i>Trypanosoma cruzi</i>treated with benznidazole
dc.typearticle

Files

Collections

Artículo Científico Publicado